The Medtronic and Johnson & Johnson-backed epilepsy treatment system provider floated at the top of its range and saw its shares rise 47% on their first day.
NeuroPace, a US-based epilepsy treatment device developer backed by medical device maker Medtronic and pharmaceutical firm Johnson & Johnson, raised $102m yesterday in an initial public offering on the Nasdaq Global Select Market. The company priced 6 million shares at $17 each, at the upper end of the $15 to $17 range for the offering.…
This content is only accessible to subscribers. If you are a subscriber, please sign in. Otherwise, if you would like to try before you buy and haven't previously taken out a free trial, you can do so below. You can also see details on subscriptions by clicking the Subscription Options button.
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.